Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NKGen Biotech ( (NKGN) ) just unveiled an update.
On May 5, 2025, NKGen Biotech entered into a Stock Purchase Agreement with its CEO and Chairperson, Paul Y. Song, involving the sale of 20,849,725 shares and warrants to purchase additional shares, valued at $2.65 million. This investment aims to accelerate the company’s Phase 2 clinical trial for Alzheimer’s Disease and address financial obligations. The transaction, approved by the Board and Audit Committee, reflects confidence in NKGen’s potential and aligns with the company’s strategic objectives.
More about NKGen Biotech
NKGen Biotech, Inc. is a clinical-stage biotechnology company based in Santa Ana, California, focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics.
Average Trading Volume: 3,820,537
Technical Sentiment Signal: Sell
Current Market Cap: $5.95M
Find detailed analytics on NKGN stock on TipRanks’ Stock Analysis page.